ISA Pharmaceuticals embarks on EUR 4 million Cancer Vaccine development track awarded by CTMM

March 22, 2011

ISA Pharmaceuticals B.V., a leader in the development of immunotherapeutic products for oncology and infectious diseases, announced that CTMM, an agency of the Dutch Ministry of Economic Affairs, has awarded ISA and partners a EUR 4 million grant to finance the further optimization of its SLP based platform. Gerard Platenburg, Chief Executive Officer of ISA said: “CTMM acknowledges, by this grant, the uniqueness of our platform and we are very pleased to further solidify the scientific basis of ISA. Grants under this special scheme are awarded to innovative projects with a strong commercial potential. This will be instrumental in further development of ISA.” For the development of new SLP based therapies it is crucial to further optimize e.g. dosing, and methods of administration. In this project ISA will collaborate with 4 renowned groups (LUMC, Leiden University, Utrecht University and Percuros B.V.) which are all specialized in the important areas of this project: immunology, chemistry, imaging, pharmacy and cancer therapy.

Home > Press Releases > ISA Pharmaceuticals embarks on EUR 4 million Ca...

© 2019 Aglaia Oncology Funds | Privacy | Sitemap
Aglaia Oncology Funds